This broad evaluation disclosed a uniform pattern of elevated PPP4C expression in numerous cancers, notably associated with adverse results, particularly in patients with liver hepatocellular carcinoma (LIHC) and kidney renal clear cell carcinoma (KIRC) (Figure 3K). The gene discussed is PPP4C; the disease is cancer.